Introduction
The use of transgenic animals in genetic toxicology has been the subject of review in recent reports (Ashby and Tinwell, 1994; Tennant et al, 1994) . We are currently validating the Muta™Mouse (lacTJgalE) assay to detect mutation in a range of tissues using known mutagens/carcinogens (Brooks et al, 1995) . We are further validating a new positive selection system, developed by Ingeny BV in The Netherlands (Gossen and Vijg, 1993) and described by Dean and Myhr (1994) . This report describes the investigation of mutations in the tissues (skin, stomach or liver) of Mut™Mice following a single oral or topical dose of the direct-acting mutagens, ^V-methyl-^V'-nitro-VV-nitrosoguanidine (MNNG) or 1-chloromethylpyrene (CMP).
MNNG is a locally-active carcinogen that produces tumours at the site of application; skin tumours are produced after topical application (Takayama et al, 1971) and glandular stomach tumours are produced after oral dosing (Tomatis et al, 1978) . MNNG is a direct-acting mutagen, and in vivo mutagenicity tests have shown activity in the mouse bone marrow micronucleus test after i.p. injection, but negative or equivocal results were obtained after oral dosing (Ashby and Mirkova, 1987) . A rat liver unscheduled DNA synthesis (UDS) assay has given an equivocal result (Mirsalis et al., 1982) , whereas positive UDS assays have been reported in the rat stomach after oral dosing with MNNG (Burlinson, 1989; Kennelly et al, 1993; Ohsawa et al, 1994) .
CMP is also a direct-acting mutagen and has shown biological activity after topical administration to mice, including the induction of a high level of DNA adducts by the 32 Ppostlabelling technique, potent skin-sensitising potential in the local lymph node assay and a hyperplastic response in the sebaceous gland suppression test (Ashby et al, 1990) . Based on these data, it was considered to be a probable potent human skin carcinogen. Orally dosed CMP has given negative results in a rat stomach UDS assay (Kennelly et al, 1993 ) and a mouse bone marrow micronucleus test (Ashby et al, 1990) .
This report describes preliminary information in pairs of animals of the investigation of mutation in target and nontarget organs; the skin and liver following a single topical treatment of MNNG, mutation in the skin following a single topical treatment of CMP, mutation in the stomach and liver after a single oral dose of MNNG and mutation in the stomach following a single oral dose of CMP.
Materials and methods

Chemicals
MNNG was obtained from Sigma Chemical Company, Poole, Dorset. It was prepared for oral dosing as a solution in water, and for skin application as a solution in acetone. CMP was a gift from Dr J.Ashby, Zeneca CTL, Alderley Park, Macclesfield, Cheshire. It was prepared for oral dosing as a suspension in com oil, and for skin application as a solution in acetone. Dimethylbenz[a]anthracene (DMBA) was obtained from Sigma Chemical Company and was prepared as a solution in acetone for skin application. All formulations were prepared immediately prior to dosing.
Animals and treatment
All procedures to be carried out on live animals as part of this study were subject to the provisions of United Kingdom National Law, in particular the Animals (Scientific Procedures) Act, 1986. Male Muta™Mice aged 8-10 weeks were supplied by Hazleton Research Products, Pennsylvania, USA. For the oral dosing study, groups of two animals each received a single oral gavage dose of MNNG (50 or 100 mg/kg) or CMP (25 or 50 mg/kg) either 3, 7 or 10 days prior to being killed. A dosing volume of 10 ml/kg body weight was used. Control animals were untreated and killed 3 or 10 days after the start of the experiment For the skin painting study, pairs of animals each received a single dose of MNNG (250 or 500 u.g) or CMP (5 or 10 (lg) applied to a shorn area of the back by syringe in 0.1 ml acetone either 7, 14 or 21 days prior to killing. Animals dosed with DMBA (40 |lg in 0.1 ml acetone) were killed 14 days after treatment. Control animals were dosed with 0.1 ml acetone and sacrificed after 7 or 21 days. All animals were killed by CO 2 asphyxiation followed by cervical dislocation. Tissues were removed from the animals, flash-frozen in liquid nitrogen and stored at -80°C until processed.
Bacteria
The proprietary strain of Eschcnchia coli C lac~ galE~ Kari (galE~ Amp r ) was developed (Gossen and Vijg, 1993) and supplied by J.Gossen and J.Vijg, Ingeny BV, Leiden, The Netherlands The preparation of bacterial cultures was carried out as described in Brooks et al. (1995) .
DNA isolation and packaging
Prior to digestion, the tissue samples were prepared in the following way a sample of skin from the site of application was cut into small pieces into 5 ml lysis buffer (20 mM Na 2 EDTA, 150 mM NaCl, 10 mM Tns pH 8.0) and incubated at 65°C for 15 min. The stomach was thawed and the glandular portion was gently scraped into 5 ml lysis buffer and homogenized, twisting the pestle slowly. A thawed liver sample was gently homogenized in 5 ml lysis buffer. The isolation of DNA from these tissues and subsequent packaging procedures have been described previously by Brooks et al (1995) .
Results
The mutation frequencies observed in the DNA extracted from the stomachs of Muta™Mice after a single oral dose of MNNG or CMP are shown in Table I and Figure 1 . The results show that a single oral exposure of MNNG at doses of 50 or 100 mg/kg increased the mutation frequency in groups of two animals of stomach DNA at 3, 7 and 10 days after exposure, in agreement with a previous report by Brault et al. (1996) . No clear increases were observed at any time after exposure to 25 or 50 mg/kg CMP. The liver DNA extracted from the MNNG-treated mice showed no clear increases in mutation (Table II) .
The mutation frequencies seen in the DNA extracted from the skin of groups of two Muta™Mice 7, 14 or 21 days after a single topical application of MNNG (250 or 500 |ag) or CMP (5 or 10 (i.g) or 14 days after a single topical exposure to the positive control compound, DMBA (40 ng), are shown in Table III and Figure 2 . All test compounds showed consistent positive increases in mutation frequency at all doses and time points with the magnitude of response being MNNG > DMBA > CMP. No apparent increases were seen in the stomach DNA from the MNNG topically-treated animals (Table IV) . All the results are summarized in Table V .
Discussion
The use of transgenic animals affords great potential for the detection of potential chemical carcinogens in target organs. The assays described here were performed primarily to determine the target organ-specificity of the direct-acting mutagens, MNNG and CMP, after oral or topical application. MNNG is a direct-acting mutagen and a known glandular stomach carcinogen after oral dosing in rodents (Tomatis et al., 1978) . Exposure of Muta™Mouse to a single oral dose (50 or 100 mg/kg) of MNNG showed consistent increases in mutation frequency of glandular stomach DNA in all mice at each of the points (3, 7 or 10 days) examined. There was no obvious time-effect relationship. No obvious increases in mutation frequency were seen in liver DNA after a single oral dose of MNNG (100 mg/kg). In other in vivo mutagenicity tests in rodents investigating stomach or liver, unscheduled DNA synthesis (UDS) has been detected in rat stomach after a single oral dose of 25 or 50 mg/kg MNNG (Burlinson et al., 1991; Kennelly et al, 1993; Ohsawa et al, 1993) and orally dosed MNNG (50 mg/kg) has given an equivocal result in the rat liver UDS assay (Mirsalis et al, 1982) . The results from gene mutation studies with Muta™Mouse are, therefore, in accord with carcinogenicity studies and UDS assays carried out with MNNG, confirming activity in the glandular stomach. CMP is a potent direct-acting mutagen (Ashby et al., 1990) , although its carcinogenicity is unknown. Exposure of Muta™Mouse to a single oral dose of CMP (25 or 50 mg/kg) did not result in any detectable increase in mutation frequency in glandular stomach DNA of groups of two animals up to 10 days after dosing. Although CMP does induce UDS in rat hepatocytes treated in vitro, UDS assays in rat stomach after a single oral dose of CMP (1-60 mg/kg) have yielded negative results (Kennelly et al., 1993) . However, 32 P-postlabelling analysis has shown a high level of adducts in gastric stomach cell DNA and DNA fragmentation has been observed in the Comet assay, both after a single oral dose of 30 mg/kg CMP (Kennelly et al., 1993) . Why DNA interaction in vivo is not manifest as UDS or gene mutation is not clear and further investigation using different treatment regimes or sample times might prove useful.
MNNG produces skin tumours when applied dermally to rodents (Takayama et al., 1971) . The single application of MNNG (250 or 500 ug) in acetone to the shorn skin of Muta™Mice increased the mutation frequency of skin DNA at each of the timepoints examined after dosing (7, 14 and 21 days).
CMP is probably a potent human skin carcinogen, based on the hyperplastic response obtained in the sebaceous gland suppression assay, its potent skin sensitizing activity in the local lymph node assay and its reactivity to DNA in the 32 Ppostlabelling assay (Ashby et al., 1990) . A single application of CMP (5 or 10 |ig) in acetone to the shorn skin of Muta™Mice increased the mutation frequency at each of the timepoints (7, 14 and 21 days), although there was no evidence of a time-effect or dose-effect relationship. These increases, however, were not as high as seen with the MNNG-treated animals. The positive control compound, DMBA (40 \ig), also increased the mutation frequency at the only timepoint examined (14 days), consistent with earlier reports (Myhr, 1991; Ashby et al. 1993) .
These results are a preliminary part of an ongoing programme in our laboratory to study the organ-specificity of some known mutagens/carcinogens using the Muta™Mouse positive selection system. Clearly, to generate statistically-meaningful data in order to identify weaker positive effects, larger groups of animals (at least five) would be required. The unequivocal positive results seen in this study using small groups of animals do serve to guide further studies with these chemical compounds. Using only two animals per group means that we can only be confident in the large increases but we cannot be certain that the negative results are valid. It would, however, be difficult to justify exposing additional animals to treatments 
